- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | IMMUNOVIA AB: Immunovia discovery study published in top protein research journal | 3 | Cision News | ||
| Do | Immunovia AB: End of the Year 2024 Letter from Immunovia CEO Jeff Borcherding | 82 | PR Newswire | LUND, Sweden, Dec. 19, 2024 /PRNewswire/ -- As we near the holidays and year end, I am energized by what Immunovia has accomplished in 2024 and the opportunities... ► Artikel lesen | |
| Mi | IMMUNOVIA AB: Immunovia CEO and board members announce intention to fully exercise their TO2 warrants | 1 | Cision News | ||
| Mo | IMMUNOVIA AB: Immunovia to host a webcast with the opportunity to learn more about the positive clinical validation of its next-generation pancreatic cancer test | 1 | Cision News | ||
| 11.12. | IMMUNOVIA AB: Immunovia announces financial calendar for financial year 2025/2026 | 3 | Cision News | ||
| 09.12. | Immunovia AB: Immunovia announces positive outcome and strong accuracy in the clinical validation of its next-generation test for pancreatic cancer | 80 | PR Newswire | LUND, Sweden, Dec. 9, 2024 /PRNewswire/ -- Immunovia (STO: IMMNOV), the pancreatic cancer diagnostics company, today announces the successful completion of the... ► Artikel lesen | |
| IMMUNOVIA Aktie jetzt für 0€ handeln | |||||
| 28.11. | IMMUNOVIA AB: Immunovia to present at the Redeye Technology & Life Science Day | 2 | Cision News | ||
| 27.11. | Immunovia AB: Immunovia Publishes Interim Report for January-September 2024 | 225 | PR Newswire | LUND, Sweden, Nov. 27, 2024 /PRNewswire/ --
July-September 2024
Net sales, which for the quarter only included royalties, amounted to 235 KSEK (488).Net earnings amounted to -51.1... ► Artikel lesen | |
| 15.11. | IMMUNOVIA AB: Immunovia presents model-development study results at meeting of the Collaborative Group of the Americas-Inherited Gastrointestinal Cancers | 3 | Cision News | ||
| 12.11. | Immunovia AB: Invitation to Immunovia's Q3 presentation | 135 | PR Newswire | LUND, Sweden, Nov. 12, 2024 /PRNewswire/ -- Immunovia will publish its third quarter 2024 results on November 27, 2024 at 8:30 am CET. Analysts, investors and media are invited to a webcast... ► Artikel lesen | |
| 07.11. | Immunovia AB: Immunovia presents data from model development study at meeting of the PRECEDE pancreatic cancer research consortium | 258 | PR Newswire | SAN DIEGO, Nov. 7, 2024 /PRNewswire/ -- Immunovia (NASDAQ STOCKHOLM: IMMNOV), the pancreatic cancer diagnostics company, will present an update on its next-generation test at the annual... ► Artikel lesen | |
| 07.10. | Immunovia AB: Immunovia has successfully acquired all blood samples required to clinically validate its next-generation test for pancreatic cancer | 340 | PR Newswire | LUND, Sweden, Oct. 7, 2024 /PRNewswire/ -- Immunovia (IMMNOV: Nasdaq Stockholm), the pancreatic cancer diagnostics company, today announces that the company has acquired all blood samples... ► Artikel lesen | |
| 02.10. | Immunovia AB: Immunovia completes analytical validation of its next-generation pancreatic cancer test | 285 | PR Newswire | LUND, Sweden, Oct. 2, 2024 /PRNewswire/ -- Immunovia (IMMNOV: Nasdaq Stockholm), the pancreatic cancer diagnostics company, today announces that the company has completed the analytical validation... ► Artikel lesen | |
| 30.09. | Change in number of shares and votes in Immunovia AB (publ) | 215 | PR Newswire | LUND, Sweden, Sept. 30, 2024 /PRNewswire/ -- During September 2024, the registered number of shares and votes in Immunovia AB (publ) ("Immunovia") has increased due to the rights issue of... ► Artikel lesen | |
| 27.09. | Nasdaq Stockholm AB: New equity right for trading, Immunovia AB (publ) | 263 | GlobeNewswire | At the request of Immunovia AB (publ), Immunovia AB equity rights TO 2 and TO 3
will be traded on Nasdaq Stockholm as from September 30, 2024.
IMMNOV TO 2
Security name: Immunovia AB TO 2
---------------------------------
Short... ► Artikel lesen | |
| 16.09. | Immunovia AB: Immunovia presents data from model development study at 2024 AACR Advances in Pancreatic Cancer medical conference | 393 | PR Newswire | LUND, Sweden, Sept. 16, 2024 /PRNewswire/ -- Immunovia (IMMNOV: Nasdaq Stockholm), the pancreatic cancer diagnostics company, today presented detailed model-development study results at the... ► Artikel lesen | |
| 12.09. | IMMUNOVIA AB: Immunovia carries out a directed issue of units to guarantors in connection with the completed rights issue | 2 | Cision News | ||
| 03.09. | IMMUNOVIA AB: Immunovia announces final outcome in rights issue | 2 | Cision News | ||
| 02.09. | IMMUNOVIA AB: Immunovia publishes preliminary outcome in rights issue | 1 | Cision News | ||
| 13.08. | Nasdaq Stockholm AB: Listing of units rights and paid subscription units of Immunovia AB | 363 | GlobeNewswire | With effect from August 16, 2024, the unit rights of Immunovia AB will be
traded on the list for Equity rights. Trading will continue up until and
including August 27, 2024.
Instrument: Unit rights... ► Artikel lesen |
Seite:
1 2 3 Weiter >>
46 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| TELADOC HEALTH | 9,012 | -0,60 % | Teladoc Health Aktie: Kein Grund zur Freude | Der Telemedizin-Spezialist Teladoc Health verzeichnet zum Jahresende eine merkliche Abwärtsbewegung an der Börse. Der aktuelle Aktienkurs liegt bei 9,90 EUR (Stand: 14. Dezember), was einem monatlichen... ► Artikel lesen | |
| BECTON DICKINSON | 218,10 | -0,14 % | Becton Dickinson: Perle in einem gecrashten Sektor? | Becton Dickinson ist an der zentralen Unterstützung der letzten Jahre angekommen, nie Bewertung war niemals niedriger Den vollständigen Artikel lesen ... ► Artikel lesen | |
| HIMS & HERS HEALTH | 24,930 | -0,68 % | Hims & Hers Stock: Growth, Noise, and Where to Focus Now | ||
| DEXCOM | 76,90 | +0,17 % | Kurs von Dexcom steigt etwas (75,3822 €) | Am US-amerikanischen Aktienmarkt liegt der Anteilsschein von Dexcom aktuell im Plus. Zuletzt zahlten Investoren für die Aktie 78,35 US-Dollar. Heute hat sich an der US-amerikanischen Börse die Dexcom-Aktie... ► Artikel lesen | |
| INVITAE | 0,110 | 0,00 % | Invitae Aktie: Drastischer Kursverfall trotz Umsatzwachstum | Der Aktienkurs des Biotechnologieunternehmens Invitae ist in den letzten Tagen stark eingebrochen. Am 8. September fiel der Kurs um 25% auf 0,0003 USD, was einen besorgniserregenden Trend fortsetzt.... ► Artikel lesen | |
| ATOSSA THERAPEUTICS | 0,934 | +0,65 % | Atossa Therapeutics, Inc.: Atossa Therapeutics Announces Full Results from Phase 2 KARISMA-Endoxifen Study Demonstrating Statistically Significant Reductions in Mammographic Breast Density | 1 MG Dose (Z)-Endoxifen Shows Potential as a Well-Tolerated, Preventative Therapy for Premenopausal Women at Risk of Developing Breast Cancer Data to be Presented in a Poster Spotlight Session During... ► Artikel lesen | |
| EVOFEM BIOSCIENCES | - | - | Evofem Biosciences, Inc.: Evofem Biosciences Announces Financial Results for the Third Quarter of 2024 | - Improved loss from operations by 31% -
- Acquired SOLOSEC, a commercially attractive, single-dose oral antibiotic FDA-approved to treat two pervasive sexual health... ► Artikel lesen | |
| SONOMA PHARMACEUTICALS | 2,520 | 0,00 % | Sonoma Pharmaceuticals, Inc. - S-8, Securities to be offered to employees in employee benefit plans | ||
| RYMAN HEALTHCARE | 2,300 | -0,78 % | RYMAN HEALTHCARE LIMITED: Ongoing Disclosure Notice - Multiple | ||
| CYTOSORBENTS | 0,814 | -6,86 % | CytoSorbents; Converge Biotech: CytoSorbents And Converge Biotech Announce Strategic Partnership to Expand Sepsis and Critical Care Treatment with CytoSorb in India | PRINCETON, N.J. and HYDERABAD, India, Nov. 11, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit... ► Artikel lesen | |
| TEMPEST THERAPEUTICS | 0,699 | -1,96 % | Tempest Therapeutics: Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | BRISBANE, Calif., Dec. 06, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-class1 targeted and immune-mediated therapeutics... ► Artikel lesen | |
| ONTRAK | 1,440 | -1,37 % | OTRK-Aktie erreicht 52-Wochen-Tief bei 1,58 US-Dollar | ||
| PATTERSON COMPANIES | 29,400 | -1,34 % | Patient Square Capital Buying Patterson Companies In $4.1 Billion Deal | ||
| STAAR SURGICAL | 23,370 | -1,72 % | 10% Owner Of Staar Surgical Purchased $1.95M In Stock | ||
| SENSEONICS | 0,402 | -10,55 % | Senseonics-Direktor Roeder erwirbt Aktien im Wert von 135.500 US-Dollar |
IMMUNOVIA AB gehört der Branche Gesundheitswesen an. Der aktuelle Kurs liegt bei 0,037 Euro und damit -1,08 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu IMMUNOVIA AB finden Sie auf Wallstreet Online.
